Pfizer trades up with Rigel’s Veppanu deal done
Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed.
